Atherosclerosis is an age-associated, multifactorial process driven by immune activation and inflammation. Ongoing clinical trials aim to establish the role of mesenchymal stromal cells (MSCs) as therapeutic agents in atherosclerosis. The beneficial effects of MSCs derive from their immune-modulatory properties. Understanding the impact of aging and age-associated conditions (i.e., type 2 diabetes mellitus and atherosclerosis) on MSC function is key to maximizing their therapeutic potency. The aim of this study was to assess the effect of chronological and biological aging on human MSCmediated CD4+ T-cell suppression. To this end human MSCs were isolated from adipose tissue and the MSC:CD4+ T-cell suppression was assessed in a coculture system. MSCs from elderly donors (≥65 years) had significantly lower T-cell suppressive capacity compared to those from donors <65 years (p = 0.003). Furthermore, MSCs from patients with atherosclerosis and type 2 diabetes mellitus were less efficient at suppressing T-cell proliferation (atherosclerosis, p = 0.02; type 2 diabetes mellitus, p = 0.04; compared to nondisease controls). Sex and tobacco use did not impact the immunosuppressive capacity of MSCs. In summary, this study demonstrates that advanced age, atherosclerosis and type 2 diabetes mellitus reduce the functional potency of MSCs. Optimizing the criteria for the selection of MSC donors could enhance the results of cellbased therapies. 
